Shields C L, Shields J A, Gross N E, Schwartz G P, Lally S E
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
Ophthalmology. 1997 Aug;104(8):1265-76. doi: 10.1016/s0161-6420(97)30148-1.
The purpose of this investigation is to report the clinical features of patients with uveal metastases seen at a major ocular oncology center.
DESIGN/PARTICIPANTS: A retrospective chart review was performed on all patients with uveal metastases evaluated at an ocular oncology outpatient facility over a 20-year period.
To assess the systemic and ophthalmic features of uveal metastases.
A total of 950 uveal metastases were diagnosed in 520 eyes of 420 consecutive patients. Of the 950 metastatic foci, the uveal involvement included iris in 90 (9%), ciliary body in 22 (2%), and choroid in 838 (88%). The total number of uveal metastases per eye was 1 (71%) in 370 eyes, 2 (12%) in 63 eyes, and 3 or more (17%) in 87 eyes. The mean number of uveal metastases per eye was two (median, one). Iris metastases presented most often as a yellow-to-white solitary nodule in the inferior quadrant. Ciliary body metastases typically presented as a solitary, sessile, or dome-shaped yellow mass in the inferior quadrant, but were difficult to visualize directly. The choroidal metastases typically were yellow in color, plateau shaped, and associated with subretinal fluid. In the 479 eyes with choroidal metastases, the epicenter of the main tumor was found in the macular area in 59 eyes (12%), between the macula and equator in 383 eyes (80%), and anterior to the equator in 37 eyes (8%). The mean size of the main (largest) choroidal tumor in each eye was 9 mm in base and 3 mm in thickness. At the time of ocular diagnosis, 278 patients (66%) reported a history of a primary cancer and 142 patients (34%) had no history of a cancer. Subsequent evaluation of these 142 patients after the ocular diagnosis of uveal metastasis showed a primary tumor in the lung in 50 patients (35%), breast in 10 (7%), others in 9 (6%), and no primary site was found in 73 patients (51%). Nearly half of the patients with no known primary site eventually died of diffuse metastatic disease. In the entire group of 420 patients, the uveal metastasis came from a primary cancer of the breast in 196 (47%), lung in 90 (21%), gastrointestinal tract in 18 (4%), kidney in 9 (2%), skin in 9 (2%), prostate in 9 (2%), and other cancers in 16 (4%). In 73 cases (17%), the primary site was never established despite systemic evaluation by medical oncologists.
Iris, ciliary body, and choroidal metastases have typical clinical features that should suggest the diagnosis. The choroid is the most common site for uveal metastases, and the tumors occur most often in the posterior pole of the eye with an average of two tumors per eye. Approximately one third of patients have no history of primary cancer at the time of ocular diagnosis. Breast and lung cancers represent more than two thirds of the primary tumor sites.
本研究旨在报告一家大型眼科肿瘤中心收治的葡萄膜转移瘤患者的临床特征。
设计/研究对象:对一家眼科肿瘤门诊20年间评估的所有葡萄膜转移瘤患者进行回顾性病历审查。
评估葡萄膜转移瘤的全身和眼部特征。
420例连续患者的520只眼中共诊断出950处葡萄膜转移瘤。在950个转移灶中,葡萄膜受累情况为:虹膜90处(9%),睫状体22处(2%),脉络膜838处(88%)。每只眼中葡萄膜转移瘤的总数为1个(71%),共370只眼;2个(12%),共63只眼;3个或更多(17%),共87只眼。每只眼中葡萄膜转移瘤的平均数为2个(中位数为1个)。虹膜转移瘤最常表现为下象限的黄白色孤立结节。睫状体转移瘤通常表现为下象限的孤立、无柄或圆顶形黄色肿物,但难以直接观察到。脉络膜转移瘤通常为黄色,呈平台状,并伴有视网膜下液。在479只患有脉络膜转移瘤的眼中,主要肿瘤的中心位于黄斑区的有59只眼(12%),位于黄斑与赤道之间的有383只眼(80%),位于赤道前方的有37只眼(8%)。每只眼中主要(最大)脉络膜肿瘤的平均大小为基底9mm,厚度3mm。在眼部诊断时,278例患者(66%)有原发性癌症病史,142例患者(34%)无癌症病史。对这142例葡萄膜转移瘤眼部诊断后的患者进行后续评估发现,50例患者(35%)原发性肿瘤位于肺部,10例(7%)位于乳腺,9例(6%)位于其他部位,73例患者(51%)未发现原发性部位。近一半无已知原发性部位的患者最终死于弥漫性转移性疾病。在420例患者的整个队列中,葡萄膜转移瘤来自乳腺癌196例(47%),肺癌90例(21%),胃肠道癌18例(4%),肾癌9例(2%),皮肤癌9例(2%),前列腺癌9例(2%),其他癌症16例(4%)。在73例(17%)患者中,尽管医学肿瘤学家进行了全身评估,但原发性部位仍未确定。
虹膜、睫状体和脉络膜转移瘤具有典型的临床特征,有助于诊断。脉络膜是葡萄膜转移瘤最常见的部位,肿瘤最常发生在眼后极,每只眼平均有两个肿瘤。约三分之一的患者在眼部诊断时无原发性癌症病史。乳腺癌和肺癌占原发性肿瘤部位的三分之二以上。